Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007

Capsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an are...

Full description

Bibliographic Details
Main Authors:	Norheim, G, Mueller, JE, Njanpop-Lafourcade, B-M, Delrieu, I, Findlow, H, Borrow, R, Xie, O, Nagaputra, J, Ramasamy, R, Dold, C, Tamekloe, TA, Rollier, CS, Watt, H, Kere, AB, Næss, LM, Pollard, AJ
Format:	Journal article
Language:	English
Published:	Elsevier 2018

Similar Items

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies.
by: Xie, O, et al.
Published: (2012)

Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis
by: Awanye, A, et al.
Published: (2019)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
by: Sheerin, D, et al.
Published: (2022)

Burden of Pneumococcal Disease in Northern Togo before the Introduction of Pneumococcal Conjugate Vaccine.
by: Jennifer C Moïsi, et al.
Published: (2017-01-01)

Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.
by: Nagaputra, J, et al.
Published: (2014)

Capsular Switching in Invasive Neisseria meningitidis, Brazil
by: Terezinha M. P. P. Castiñeiras, et al.
Published: (2012-08-01)

The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.
by: Rollier, C, et al.
Published: (2014)

Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial
by: Chang, C-M, et al.
Published: (2022)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
by: Dold, C, et al.
Published: (2023)

Synthesis of Neisseria meningitidis X capsular polysaccharide fragments
by: Laura Morelli, et al.
Published: (2012-10-01)

Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.
by: Caroline L Trotter, et al.
Published: (2013-01-01)

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on neisseria meningitidis recombinant porA protein: a comparison in mice
by: Mehta, O, et al.
Published: (2014)

Identification of Streptococcus suis Meningitis through Population-Based Surveillance, Togo, 2010–2014
by: Haoua Tall, et al.
Published: (2016-07-01)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
by: Dylan Sheerin, et al.
Published: (2022-06-01)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
by: Sheerin, D, et al.
Published: (2021)

Impact of reducing complement inhibitor binding on the immunogenicity of native neisseria meningitidis outer membrane vesicles
by: Daniels-Treffandier, H, et al.
Published: (2016)

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein.
by: Lucidarme, J, et al.
Published: (2011)

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.
by: Ojas H Mehta, et al.
Published: (2014-01-01)

Recent advances in lipopolysaccharide-based glycoconjugate vaccines
by: Zhu, H, et al.
Published: (2021)

Neisseria meningitidis Serogroup C Clonal Complex 10217 Outbreak in West Kpendjal Prefecture, Togo 2019
by: Alicia R. Feagins, et al.
Published: (2022-04-01)

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
by: Valente Pinto, M, et al.
Published: (2020)

Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.
by: Helene Daniels-Treffandier, et al.
Published: (2016-01-01)

Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007.
by: Rose, A, et al.
Published: (2010)

Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England
by: Shamez Ladhani, et al.
Published: (2016-02-01)

Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial
by: Rollier, CS, et al.
Published: (2022)

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component.
by: Sheerin, D, et al.
Published: (2019)

Correlates of protection against Neisseria Meningitidis.
by: Pollard, A
Published: (2016)

Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009
by: Shamez N. Ladhani, et al.
Published: (2012-01-01)

An OMV vaccine derived from a capsular group B meningococcus with constitutive FetA expression: preclinical evaluation of immunogenicity and toxicity
by: Norheim, G, et al.
Published: (2015)

Preparation of ConjugateD Neisseria Meningitidis Type A Capsular Polysaccharide with Recombinant Protein of Hepatitis B as an Immunogen
by: Mahboobeh Mohamadamini, et al.
Published: (2016-01-01)

Assessment of a two-step nucleic acid amplification assay for detection of Neisseria meningitidis followed by capsular genogrouping
by: Maria C Rebelo, et al.
Published: (2006-11-01)

Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil
by: David E Barroso, et al.
Published: (2007-09-01)

Development of natural immunity to Neisseria meningitidis.
by: Pollard, A, et al.
Published: (2001)

The human host defense peptide LL-37 interacts with Neisseria meningitidis capsular polysaccharides and inhibits inflammatory mediators release.
by: Susu M Zughaier, et al.
Published: (2010-10-01)

Characterization of some Togo surface waters
by: Y. Boukari, et al.
Published: (1999-06-01)

Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007.
by: Angela M C Rose, et al.
Published: (2010-06-01)

Sequence conservation of pilus subunits in Neisseria meningitidis.
by: Cehovin, A, et al.
Published: (2010)

Phase variation of Opa proteins of Neisseria meningitidis and the effects of bacterial transformation
by: Sadarangani, M, et al.
Published: (2016)

Estandarización de un procedimiento espectrofotométrico para la cuantificación de polisacárido capsular de Neisseria meningitidis serogrupo X
by: Felix Cardoso-San Jorge, et al.
Published: (2022-06-01)

Protective immune response against Neisseria meningitidis serogroup B after immunization with peptides mimicking a capsular polysaccharide epitope
by: Tamara Menéndez, et al.